[PRACTICE NOTE] The Next Chapter of Commercial Excellence in Pharma
Disciplines rarely arrive because someone invented them. They arrive because the condition that used to limit performance stopped being the condition that limits it. Commercial organizations tend to name a new capability only after the previous one has quietly run out of room. Pharma has done this three times, and the pattern is legible enough to anticipate the fourth.
The history of commercial excellence in this industry reads as a sequence of constraints relieved. Each discipline was a correct answer to the binding constraint of its own period, and each one remains necessary. The useful question is which constraint binds now, because the next chapter is always an answer to that.
Sales excellence answered the problem of access
When the modern commercial model took shape, access to the prescriber was the scarce resource. Physicians were reachable in person, their time was the gate, and the companies that organized best around that gate won. The answer was reach, frequency, territory design and relationship capital inside the clinical community. Sales excellence became a real discipline, with its own analytics, its own career path and its own vocabulary of coverage and share of voice.
Field deployment remains the most mature measurement system in most commercial organizations. That maturity was earned rather than inherited, built over decades of deciding whom to see, how often and with what. The constraint it was designed for has largely loosened, which is a different claim from saying the discipline stopped mattering.
Marketing excellence answered the problem of attention
Access eventually stopped being the hardest part of the job. As categories filled and evidence multiplied, the scarce resource became attention and credibility rather than minutes in a waiting room. A physician could be reached and still remain unpersuaded, and persuasion turned out to need different machinery than presence.
Marketing excellence answered that constraint with narrative, evidence generation, segmentation and message discipline. It built the capability to say one coherent thing across many markets and to support it with data a clinician would accept. Publication planning, medical education and brand strategy all matured inside this chapter. The craft involved is considerable and often underestimated by people who have never attempted it.
Launch excellence answered the problem of the first window
Analysis of brand histories then revealed something uncomfortable about timing. Much of a product's lifetime trajectory tends to be set in its first window, and launches that miss that window rarely recover the ground later. The constraint had moved again, this time to orchestration under time pressure.
Launch excellence answered it with readiness, orchestration and speed to peak. It brought disciplined sequencing to a moment that organizations used to manage with goodwill and heroics. Readiness reviews, milestone governance and cross functional launch teams all came out of this chapter. Of the three, it is the one that most resembles an operating discipline rather than a functional specialty.
What the three share and never resolved
Three disciplines, three correct answers, three bodies of practice that deserve respect. Each of them optimizes the creation of clinical intent, and not one of them owns whether that intent survives. The variable missing from all three accounts is experience, and it went missing causally rather than through neglect. Experience gets left to default while brand and product are designed with intent, which is a design gap rather than a failure of conviction.
Intent is the shared output. Survival of that intent belongs to nobody in particular. A therapy can be chosen by a convinced physician and still stall at an authorization queue, a copay desk or a third refill that never happens. Each of those failures sits outside the boundary of the discipline that produced the decision. I have watched capable teams run into that boundary and conclude the fault was their own.
The gap shows up in how differently the two sides describe the same engagement. Deloitte 2025 research found only 28 percent of HCPs believe pharma's engagement strategies meet their needs, against 82 percent of life sciences executives who say they are satisfied with those same strategies. A spread that wide rarely comes from a measurement error. Executives tend to measure what was delivered, while clinicians live with what was useful.
The fourth chapter has a name
The fourth chapter is Customer Excellence. Its full name carries the argument in four words, which is CX 3.0, Fit-for-Pharma, The Fourth Pillar. It is a pharma-specific interpretation of customer experience rather than an import, and that distinction is the reason it can hold where earlier forms could not. I define it as the enterprise capability that designs, delivers and scales coherent experiences across the three paths a customer travels, and that governs whether clinical intent becomes realized therapy.
The thesis underneath it is short enough to state in one line. In pharma, the commercial system is part of the therapeutic value chain, and experience is the mechanism by which that value is realized as patient and commercial impact. Written prescriptions are intent rather than realized value. The three paths are where that distinction becomes operational.
The paths are concrete rather than conceptual. The Path to Prescribe carries evidence into a clinical decision. The Path to Fulfill carries that decision through access, adjudication and dispensing. The Path to Adhere carries the therapy through the months in which benefit either accumulates or quietly disappears.
Positioned properly, Customer Excellence sits beside the other three rather than beneath them, which is the argument for treating it as the fourth pillar of commercial excellence. A capability filed inside marketing inherits marketing's boundary. The boundary is precisely the thing the new discipline exists to cross. Naming matters more here than it may appear, because institutions design what they have named and leave the rest to default.
Why the chapter is opening now
A discipline arrives when its constraint binds, not when it becomes fashionable. Five forces have tightened at the same time, and none of them substitutes for another. The first is specialty and journey complexity, which has lengthened the distance between a clinical decision and a patient on sustained therapy. The second is realization economics, which puts a number on how much of that distance gets lost.
The third is Consumer-Grade expectations arriving inside the clinical workflow rather than outside it. People who move through effortless systems all day rarely suspend that standard when they open an authorization portal. The Consumer-Grade Specification exists for that reason, as a closed set of structural conditions rather than an aspiration, covering Recognition, Anticipation, Coherence, Effort, Resolution and Visibility.
The fourth is competitors that built experience first, and it is the only force carrying proof rather than inference. Where an experience led architecture has taken share, the argument stops being theoretical for everyone else in the category. The fifth is AI, which is the decisive one on timing. AI will not make a fragmented commercial model customer-centric, it makes whatever operating system already exists faster and more scalable.
Realization economics deserves its own arithmetic. The Realization Rate is realized value divided by earned value. Earned value multiplied by one minus the Realization Rate gives Customer Value at Risk, a figure that needs no translation in a finance review. The distance between earned and realized value is value leakage, and it has a shape worth seeing.
Work published with TheyDo set out an illustrative compounded scenario rather than a benchmark. A billion dollars of earned value becomes roughly seven hundred million once prescriptions that are never filled are subtracted. Early discontinuation takes a further share of what remains. Long term adherence erosion leaves close to four hundred and fifty million realized, and no competitor takes the difference.
What separates a chapter from a management trend
Skepticism about customer experience in pharma is rational, and it has a documented origin. The first iterations were imported from industries where one organization controls the whole transaction. They did not fit a system where a physician decides, a payer funds, a benefit manager adjudicates and a pharmacy dispenses. Those iterations were rejected for good reason. The wrong lesson drawn from the rejection was that experience does not apply here, when the fitted lesson was that the imported form did not.
Being this kind of enterprise means resisting the temptation to chase fleeting management trends or quick fixes, because enduring value comes from structural change. That belief yields a workable test. A new chapter of commercial excellence arrives with five markers, which are a named discipline, an owner, a measure, a body of practice and a budget line. Launch, marketing and sales excellence each carry all five, which is why they outlasted the executives who introduced them.
Anything carrying fewer markers is an initiative, however well intentioned, and initiatives get outlasted rather than adopted. The test is uncomfortable to apply honestly. Inside the commercial organizations I have worked with, four markers missing out of five is the common finding. That pattern explains the mortality rate of customer programs better than any shortage of talent.
Sequence rather than replacement
The fourth chapter does not displace the other three, and any version of this argument that suggests otherwise deserves suspicion. Sales excellence still decides whether the right clinician meets the right evidence. Marketing excellence still decides whether that evidence arrives credible and coherent. Launch excellence still decides whether the first window gets used rather than spent.
What the fourth chapter adds is the thing the other three have never had, which is a measure of whether what they created survived. That changes how their own results read. A launch can produce strong early demand and poor realization, succeeding by its own measures while failing by the enterprise's. Until the fourth discipline exists, nobody in the commercial system is positioned to say so out loud.
Durability comes from four layers rather than from a mandate. Leadership DNA determines whether the commitment survives a quarterly miss. Organizational DNA determines who owns the seams between functions, and Operational DNA determines whether helpfulness repeats without an exceptional colleague in the room. Commercial DNA determines whether measures and incentives reward realized value or declared intent.
Key Takeaways
- Each discipline arrived when the previous constraint stopped binding. Sales excellence answered access, marketing excellence answered attention and credibility, and launch excellence answered the first window.
- All three optimize the creation of clinical intent. Not one of them owns whether that intent survives access, adjudication, dispensing and the long middle of therapy.
- Customer Excellence is CX 3.0, Fit-for-Pharma, The Fourth Pillar. It completes launch, marketing and sales excellence rather than replacing them, by measuring whether what they created actually survived.
- The earlier rejection of imported customer experience was rational. The first iterations did not fit the industry, and the wrong lesson drawn was that experience does not apply here.
- Five forces are opening the chapter at the same time. Specialty and journey complexity, realization economics, Consumer-Grade expectations inside the clinical workflow, competitors that built experience first, and AI as the decisive one on timing.
- A chapter carries five markers and an initiative carries fewer. A named discipline, an owner, a measure, a body of practice and a budget line separate structural change from a passing trend.
Diagnostic Questions to Consider
- Name which of the five forces binds hardest for the lead brand, then test whether the three existing disciplines can relieve it.
- State the Realization Rate as realized value divided by earned value for the lead brand, without estimating the figure in the room.
- Identify the single executive accountable for whether created intent becomes realized therapy, and confirm that the accountability is written down.
- Apply the five markers to the current customer experience work and count how many are genuinely present.
- Set Customer Value at Risk for one brand beside next year's promotional investment for the same brand.
Closing Reflection
Industries design what they have named. Pharma named three disciplines of commercial excellence, built genuine capability inside each and produced four decades of improvement within those boundaries. Experience was never the fourth name on that list, so it was left to default while brand and product were designed with intent. The distance between a prescribing decision and a patient still on therapy two years later is where that default now shows.
Opening a chapter is not an announcement. It assigns ownership to a stretch of the therapeutic value chain where ownership has been ambiguous, and ambiguity in that position carries a price the enterprise pays whether or not it measures it. Companies that move first will often look slower for a while, because governance work rarely photographs as well as campaign work.
The three chapters already written carried the industry to extraordinary science delivered at scale. The fourth decides how much of that science reaches the person it was made for. That measure has never existed, and the companies that build it will be the ones describing what commercial excellence means in the next decade.
About the Author
Wayne Simmons is the founder of The Customer Excellence AGENCY and the author of The Customer Excellence Enterprise (Wiley, 2024). He is founding faculty of the MS in Customer Experience Management at Michigan State University's Broad College of Business. He led global customer excellence in Pfizer's first Chief Marketing Organization and in Bayer's Customer Powerhouse.
The Customer Excellence Agency: Advancing the Pursuit of Excellence in Service of Science.
